{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T18:59:49Z","timestamp":1784833189750,"version":"3.55.0"},"reference-count":27,"publisher":"Walter de Gruyter GmbH","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,6,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Beta (\u03b2)-glucosidase 2 (GBA2) is deficient in a form of human spastic paraplegia due to defects in <jats:italic>GBA2<\/jats:italic> (<jats:italic>SPG46<\/jats:italic>). GBA2 was proposed as a modifier of Gaucher disease, a lysosomal storage disease resulting from deficient \u03b2-glucosidase 1; GBA1. Current GBA2 activity assays using artificial substrates incompletely model the activity encountered <jats:italic>in vivo<\/jats:italic>. We studied GBA2 activity, using lithocholic acid \u03b2-glucoside or glucosylceramide as natural \u03b2-glucosidase substrates in murine tissues or cultured patient fibroblasts with the pathologic genotypes: <jats:italic>Gba1<jats:sup>\u2212\/\u2212<\/jats:sup>\n                  <\/jats:italic>; <jats:italic>Gba2<jats:sup>\u2212\/\u2212<\/jats:sup>\n                  <\/jats:italic>; <jats:italic>GBA1<jats:sup>\u2212\/\u2212<\/jats:sup>\n                  <\/jats:italic>; <jats:italic>GBA2<jats:sup>+\/\u2212<\/jats:sup>\n                  <\/jats:italic> and found expected and unexpected deviations from normal controls.<\/jats:p>","DOI":"10.1515\/hsz-2018-0438","type":"journal-article","created":{"date-parts":[[2018,12,19]],"date-time":"2018-12-19T09:00:51Z","timestamp":1545210051000},"page":"745-752","source":"Crossref","is-referenced-by-count":2,"title":["Assay of \u03b2-glucosidase 2 (GBA2) activity using lithocholic acid \u03b2-3-O-glucoside substrate for cultured fibroblasts and glucosylceramide for brain tissue"],"prefix":"10.1515","volume":"400","author":[{"given":"Klaus","family":"Harzer","sequence":"first","affiliation":[{"name":"Department of Neuropediadrics, Neurometabolic Laboratory, Children\u2019s Hospital , University of T\u00fcbingen , Hoppe-Seyler-Str. 1 , D-72076 T\u00fcbingen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yildiz","family":"Yildiz","sequence":"additional","affiliation":[{"name":"Internal Medicine , Medicnova Hospital , Selemad 10 , FL-9487 Gamprin-Bendern , Liechtenstein"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Beck-W\u00f6dl","sequence":"additional","affiliation":[{"name":"Department of Medical Genetics and Applied Genomics , University of T\u00fcbingen , Calwerstr. 7 , D-72076 T\u00fcbingen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2019,1,17]]},"reference":[{"key":"2023040406525964891_j_hsz-2018-0438_ref_001_w2aab3b7c75b1b6b1ab2b1b1Aa","doi-asserted-by":"crossref","unstructured":"Aureli, M., Samarani, M., Loberto, N., Mancini, G., Murdica, V., Chiricozzi, E., Prinetti, A., Bassi, R., and Sonnino, S. (2016). Current and novel aspects on the non-lysosomal \u03b2-glucosylceramidase GBA2. Neurochem. Res. 41, 210\u2013220.","DOI":"10.1007\/s11064-016-1833-0"},{"key":"2023040406525964891_j_hsz-2018-0438_ref_002_w2aab3b7c75b1b6b1ab2b1b2Aa","doi-asserted-by":"crossref","unstructured":"Ben Bdira, F., Artola, M., Overkleeft, H.S., Ubbink, M., and Aerts, J.M. (2018). Distinguishing the differences in \u03b2-glucosylceramidase folds, dynamics, and actions informs therapeutic uses. J. Lipid Res. 59, 2262\u20132276.","DOI":"10.1194\/jlr.R086629"},{"key":"2023040406525964891_j_hsz-2018-0438_ref_003_w2aab3b7c75b1b6b1ab2b1b3Aa","doi-asserted-by":"crossref","unstructured":"Boot, R.G., Verhoek, M., Donker-Koopman, W., Strijland, A., van Marle, J., Overkleeft, H.S., Wennekes, T., and Aerts, J.M. (2007). Identification of the non-lysosomal glucosylceramidase as \u03b2-glucosidase 2. J. Biol. Chem. 282, 1305\u20131312.","DOI":"10.1074\/jbc.M610544200"},{"key":"2023040406525964891_j_hsz-2018-0438_ref_004_w2aab3b7c75b1b6b1ab2b1b4Aa","doi-asserted-by":"crossref","unstructured":"Charoenwattanasatien, R., Pengthaisong, S., Breen, I., Mutoh, R., Sansenya, S., Hua, Y., Tankrathok, A., Wu, L., Songsiriritthigul, C., Tanaka, H., Williams, S.J., et al. (2016). Bacterial \u03b2-glucosidase reveals the structural and functional basis of genetic defects in human glucocerebrosidase 2 (GBA2). ACS Chem. Biol. 11, 1891\u20131900.","DOI":"10.1021\/acschembio.6b00192"},{"key":"2023040406525964891_j_hsz-2018-0438_ref_005_w2aab3b7c75b1b6b1ab2b1b5Aa","doi-asserted-by":"crossref","unstructured":"Davidson, B.A., Hassan, S., Garcia, E.J., Tayebi, N., and Sidransky, E. (2018). Exploring genetic modifiers of Gaucher disease: the next horizon. Hum. Mutat. 39, 1739\u20131751.","DOI":"10.1002\/humu.23611"},{"key":"2023040406525964891_j_hsz-2018-0438_ref_006_w2aab3b7c75b1b6b1ab2b1b6Aa","doi-asserted-by":"crossref","unstructured":"Fuller, M., Rozaklis, T., Lovejoy, M., Zarrinkalam, K., Hopwood, J.J., and Meikle, P.J. (2008). Glucosylceramide accumulation is not confined to the lysosome in fibroblasts from patients with Gaucher disease. Mol. Genet. Metab. 93, 437\u2013443.","DOI":"10.1016\/j.ymgme.2007.11.011"},{"key":"2023040406525964891_j_hsz-2018-0438_ref_007_w2aab3b7c75b1b6b1ab2b1b7Aa","doi-asserted-by":"crossref","unstructured":"Hamler, R., Brignol, N., Clark, S.W., Morrison, S., Dungan, L.B., Chang, H.H., Khanna, R., Frascella, M., Valenzano, K.J., Benjamin, E.R., et al. (2017). Glucosylceramide and glucosylsphingosine quantitation by liquid chromatography-tandem mass spectrometry to enable in vivo preclinical studies of neuronopathic Gaucher disease. Anal. Chem. 89, 8288\u20138295.","DOI":"10.1021\/acs.analchem.7b01442"},{"key":"2023040406525964891_j_hsz-2018-0438_ref_008_w2aab3b7c75b1b6b1ab2b1b8Aa","doi-asserted-by":"crossref","unstructured":"Hammer, M.B., Eleuch-Fayache, G., Schottlaender, L.V., Nehdi, H., Gibbs, J.R., Arepalli, S.K., Chong, S.B., Hernandez, D.G., Sailer, A., Liu, G., et al. (2013). Mutations in GBA2 cause differences in beta-glycosylceramidase folds, dynamics, and actions informs therapeutic uses. autosomal-recessive cerebellar ataxia with spasticity. Am. J. Hum. Genet. 92, 245\u2013251.","DOI":"10.1016\/j.ajhg.2012.12.012"},{"key":"2023040406525964891_j_hsz-2018-0438_ref_009_w2aab3b7c75b1b6b1ab2b1b9Aa","doi-asserted-by":"crossref","unstructured":"Harzer, K., and Yildiz, Y. (2015). High \u03b2-glucosidase (GBA) activity not attributable to GBA1 and GBA2 in live normal and enzyme-deficient fibroblasts may emphasise the role of additional GBAs. Biol. Chem. 396, 1241\u20131246.","DOI":"10.1515\/hsz-2015-0144"},{"key":"2023040406525964891_j_hsz-2018-0438_ref_010_w2aab3b7c75b1b6b1ab2b1c10Aa","doi-asserted-by":"crossref","unstructured":"Harzer, K., Blech-Hermoni, Y., Goldin, E., Felderhoff-Mueser, U., Igney, C., Sidransky, E., and Yildiz, Y. (2012). Beta-glucosidase 1 (GBA1) is a second bile acid \u03b2-glucosidase in addition to \u03b2-glucosidase 2 (GBA2). Study in \u03b2-glucosidase deficient mice and humans. Biochem. Biophys. Res. Commun. 423, 308\u2013312.","DOI":"10.1016\/j.bbrc.2012.05.117"},{"key":"2023040406525964891_j_hsz-2018-0438_ref_011_w2aab3b7c75b1b6b1ab2b1c11Aa","doi-asserted-by":"crossref","unstructured":"K\u00f6rschen, H.G., Yildiz, Y., Raju, D.N., Schonauer, S., B\u00f6nigk, W., Jansen, V., Kremmer, E., Kaupp, U.B., and Wachten, D. (2013). The non-lysosomal beta-glucosidase GBA2 is a non-integral membrane-associated protein at the endoplasmic reticulum (ER) and Golgi. J. Biol. Chem. 288, 3381\u20133393.","DOI":"10.1074\/jbc.M112.414714"},{"key":"2023040406525964891_j_hsz-2018-0438_ref_012_w2aab3b7c75b1b6b1ab2b1c12Aa","doi-asserted-by":"crossref","unstructured":"Marques, A.R., Aten, J., Ottenhoff, R., van Roomen, C.P., Herrera Moro, D., Claessen, N., Vinueza Veloz, M.F., Zhou, K., Lin, Z., Mirzaian, M., et al. (2015). Reducing GBA2 activity ameliorates neuropathology in Niemann-Pick type C mice. PLoS One. 10. doi: 10.1371\/journal.pone.0135889. eCollection 2015.","DOI":"10.1371\/journal.pone.0135889"},{"key":"2023040406525964891_j_hsz-2018-0438_ref_013_w2aab3b7c75b1b6b1ab2b1c13Aa","doi-asserted-by":"crossref","unstructured":"Marschall, H.-U., Egestad, B., Matern, H., Matern, S., and Sj\u00f6vall, J. (1987). Evidence for bile acid glucosides as normal constituents in human urine. FEBS Lett. 213, 411\u2013417.","DOI":"10.1016\/0014-5793(87)81532-6"},{"key":"2023040406525964891_j_hsz-2018-0438_ref_014_w2aab3b7c75b1b6b1ab2b1c14Aa","doi-asserted-by":"crossref","unstructured":"Martin, E., Sch\u00fcle, R., Smets, K., Rastetter, A., Boukhris, A., Loureiro, J.L., Gonzalez, M.A., Mundwiller, E., Deconinck, T., Wessner, M., et al. (2013). Loss of function of glucocerebrosidase GBA2 is responsible for motor neuron defects in hereditary spastic paraplegia. Am. J. Hum. Genet. 92, 238\u2013244.","DOI":"10.1016\/j.ajhg.2012.11.021"},{"key":"2023040406525964891_j_hsz-2018-0438_ref_015_w2aab3b7c75b1b6b1ab2b1c15Aa","doi-asserted-by":"crossref","unstructured":"Matern, H., Gartzen, R., and Matern, S. (1992). Beta-glucosidase activity towards a bile acid glucoside in human liver. FEBS Lett. 314, 183\u2013186.","DOI":"10.1016\/0014-5793(92)80970-R"},{"key":"2023040406525964891_j_hsz-2018-0438_ref_016_w2aab3b7c75b1b6b1ab2b1c16Aa","doi-asserted-by":"crossref","unstructured":"Matern, H., Heinemann, H., Legler, G., and Matern, S. (1997). Purification and characterization of a microsomal bile acid beta-glucosidase from human liver. J. Biol. Chem. 272, 11261\u201311267.","DOI":"10.1074\/jbc.272.17.11261"},{"key":"2023040406525964891_j_hsz-2018-0438_ref_017_w2aab3b7c75b1b6b1ab2b1c17Aa","doi-asserted-by":"crossref","unstructured":"Orvisky, E., Sidransky, E., McKinney, C.E., Lamarca, M.E., Samimi, R., Krasnewich, D., Martin, B.M., and Ginns, E.I. (2000). Glucosylsphingosine accumulation in mice and patients with type 2 Gaucher disease begins early in gestation. Pediatr. Res. 48, 233\u2013237.","DOI":"10.1203\/00006450-200008000-00018"},{"key":"2023040406525964891_j_hsz-2018-0438_ref_018_w2aab3b7c75b1b6b1ab2b1c18Aa","doi-asserted-by":"crossref","unstructured":"Overkleeft, H.S., Renkema, G.H., Neele, J., Vianello, P., Hung, I.O., Strijland, A., van der Burg, A.M., Koomen, G.J., Pandit, U.K., and Aerts, J.M. (1998). Generation of specific deoxynojirimycin-type inhibitors of the non-lysosomal glucosylceramidase. J. Biol. Chem. 273, 26522\u2013265227.","DOI":"10.1074\/jbc.273.41.26522"},{"key":"2023040406525964891_j_hsz-2018-0438_ref_019_w2aab3b7c75b1b6b1ab2b1c19Aa","doi-asserted-by":"crossref","unstructured":"Ridley, C.M., Thur, K.E., Shanahan, J., Thillaiappan, N.B., Shen, A., Uhl, K., Walden, C.M., Rahim, A.A., Waddington, S.N., Platt, F.M., et al. (2013). \u03b2-Glucosidase 2 (GBA2) activity and imino sugar pharmacology. J. Biol. Chem. 288, 26052\u201326066.","DOI":"10.1074\/jbc.M113.463562"},{"key":"2023040406525964891_j_hsz-2018-0438_ref_020_w2aab3b7c75b1b6b1ab2b1c20Aa","doi-asserted-by":"crossref","unstructured":"Schonauer, S., K\u00f6rschen, H.G., Penno, A., Rennhack, A., Breiden, B., Sandhoff, K., Gutbrod, K., D\u00f6rmann, P., Raju, D.N., Haberkant, P., et al. (2017). Identification of a feedback loop involving \u03b2-glucosidase 2 and its product sphingosine sheds light on the molecular mechanisms in Gaucher disease. J. Biol. Chem. 292, 6177\u20136189.","DOI":"10.1074\/jbc.M116.762831"},{"key":"2023040406525964891_j_hsz-2018-0438_ref_021_w2aab3b7c75b1b6b1ab2b1c21Aa","doi-asserted-by":"crossref","unstructured":"Sultana, S., Reichbauer, J., Sch\u00fcle, R., Mochel, F., Synofzik, M., and van der Spoel, A.C. (2015). Lack of enzyme activity in GBA2 mutants associated with hereditary spastic paraplegia\/cerebellar ataxia (SPG46). Biochem. Biophys. Res. Commun. 465, 35\u201340.","DOI":"10.1016\/j.bbrc.2015.07.112"},{"key":"2023040406525964891_j_hsz-2018-0438_ref_022_w2aab3b7c75b1b6b1ab2b1c22Aa","doi-asserted-by":"crossref","unstructured":"Sultana, S., Truong, N.Y., Vieira, D.B., Wigger, J.G., Forrester, A.M., Veinotte, C.J., Berman, J.N., and van der Spoel, A.C. (2016). Characterization of the zebrafish homolog of \u03b2-glucosidase 2: A target of the drug miglustat. Zebrafish 13, 177\u2013187.","DOI":"10.1089\/zeb.2015.1152"},{"key":"2023040406525964891_j_hsz-2018-0438_ref_023_w2aab3b7c75b1b6b1ab2b1c23Aa","doi-asserted-by":"crossref","unstructured":"Tamargo, R.J., Velayati, A., Goldin, E., and Sidransky, E. (2012). The role of saposin C in Gaucher disease. Mol. Genet. Metab. 106, 257\u2013263.","DOI":"10.1016\/j.ymgme.2012.04.024"},{"key":"2023040406525964891_j_hsz-2018-0438_ref_024_w2aab3b7c75b1b6b1ab2b1c24Aa","doi-asserted-by":"crossref","unstructured":"van Weely, S., Brandsma, M., Strijland, A., Tager, J.M., and Aerts, J.M. (1993). Demonstration of the existence of a second, non-lysosomal glucocerebrosidase that is not deficient in Gaucher disease. Biochim. Biophys. Acta 1181, 55\u201362.","DOI":"10.1016\/0925-4439(93)90090-N"},{"key":"2023040406525964891_j_hsz-2018-0438_ref_025_w2aab3b7c75b1b6b1ab2b1c25Aa","doi-asserted-by":"crossref","unstructured":"Wennekes, T., Meijer, A.J., Groen, A.K., Boot, R.G., Groener, J.E., van Eijk, M., Ottenhoff, R., Bijl, N., Ghauharali, K., Song, H., et al. (2010). Dual-action lipophilic iminosugar improves glycemic control in obese rodents by reduction of visceral glycosphingolipids and buffering of carbohydrate assimilation. J. Med. Chem. 28, 689\u2013698.","DOI":"10.1021\/jm901281m"},{"key":"2023040406525964891_j_hsz-2018-0438_ref_026_w2aab3b7c75b1b6b1ab2b1c26Aa","doi-asserted-by":"crossref","unstructured":"Yildiz, Y., Matern, H., Thompson, B., Allegood, J.C., Warren, R.L., Ramirez, D.M., Hammer, R.E., Hamra, F.K., Matern, S., and Russell, D.W. (2006). Mutation of \u03b2-glucosidase 2 causes glycolipid storage disease and impaired male fertility. J. Clin. Invest. 116, 2985\u20132994.","DOI":"10.1172\/JCI29224"},{"key":"2023040406525964891_j_hsz-2018-0438_ref_027_w2aab3b7c75b1b6b1ab2b1c27Aa","doi-asserted-by":"crossref","unstructured":"Yildiz, Y., Hoffmann, P., Vom Dahl, S., Breiden, B., Sandhoff, R., Niederau, C., Horwitz, M., Karlsson, S., Filocamo, M., Elstein, D., et al. (2013). Functional and genetic characterization of the non-lysosomal glucosylceramidase 2 as a modifier for Gaucher disease. Orphanet J. Rare. Dis. 8, 151.","DOI":"10.1186\/1750-1172-8-151"}],"container-title":["Biological Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.degruyter.com\/view\/j\/bchm.2019.400.issue-6\/hsz-2018-0438\/hsz-2018-0438.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/hsz-2018-0438\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/hsz-2018-0438\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T08:42:38Z","timestamp":1680597758000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/hsz-2018-0438\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,17]]},"references-count":27,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2019,1,17]]},"published-print":{"date-parts":[[2019,6,26]]}},"alternative-id":["10.1515\/hsz-2018-0438"],"URL":"https:\/\/doi.org\/10.1515\/hsz-2018-0438","relation":{},"ISSN":["1437-4315","1431-6730"],"issn-type":[{"value":"1437-4315","type":"electronic"},{"value":"1431-6730","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1,17]]}}}